Plasma adiponectin in heart failure with and without cachexia: Catabolic signal linking catabolism, symptomatic status, and prognosis

T. Szabó; N. Scherbakov; A. Sandek; T. Kung; S. von Haehling; M. Lainscak; E. A. Jankowska; N. Rudovich; S. D. Anker; J. Frystyk; A. Flyvbjerg; A. F H Pfeiffer; W. Doehner

doi:10.1016/j.numecd.2013.04.015

Plasma adiponectin in heart failure with and without cachexia: Catabolic signal linking catabolism, symptomatic status, and prognosis

T. Szabó, N. Scherbakov, A. Sandek, T. Kung, S. von Haehling, M. Lainscak, E. A. Jankowska, N. Rudovich, S. D. Anker, J. Frystyk, A. Flyvbjerg, A. F H Pfeiffer, W. Doehner

Istituto San Raffaele Pisana

Research output: Contribution to journal › Article › peer-review

Abstract

Background and aims: Adiponectin (ADPN) as an adipose tissue hormone contributes to regulation of energy metabolism and body composition and is associated with cardiovascular risk profile parameters. Cardiac cachexia may develop as a result of severe catabolic derangement in chronic heart failure (CHF). We aimed to determinate an abnormal ADPN regulation as a link between catabolic signalling, symptomatic deterioration and poor prognosis. Methods and results: We measured plasma ADPN in 111 CHF patients (age 65±11, 90% male, left ventricular ejection fraction (LVEF) 36±11%, peak oxygen consumption (peakVO₂) 18.1±5.7l/kg*min, body mass index (BMI) 27±4 kg/m², all mean±standard deviation) and 36 healthy controls of similar age and BMI. Body composition was assessed by dual energy X-ray absorptiometry, insulin sensitivity was evaluated by homoeostasis model assessment, exercise capacity by spiroergometry. Plasma ADPN did not differ between CHF vs. controls (13.5±11.0 vs. 10.5±5.3 mg/l, p>0.4), but increased stepwise with NYHA functional class (I/II/III: 5.7±1.4/10.7±8.3/19.2±14.0 mg/l, ANOVA p2 at anaerobic threshold (r=-0.34, p

Original language	English
Pages (from-to)	50-56
Number of pages	7
Journal	Nutrition, Metabolism and Cardiovascular Diseases
Volume	24
Issue number	1
DOIs	https://doi.org/10.1016/j.numecd.2013.04.015
Publication status	Published - 2014

Keywords

Adiponectin
ADPN
AT
BMI
Cachexia
CCHF
CHF
Chronic heart failure
DEXA
HOMA
LVEF
Metabolism
NcCHF
NYHA
ProANP
RER
VE

ASJC Scopus subject areas

Medicine (miscellaneous)
Nutrition and Dietetics
Endocrinology, Diabetes and Metabolism
Cardiology and Cardiovascular Medicine

Access to Document

10.1016/j.numecd.2013.04.015

Fingerprint Dive into the research topics of 'Plasma adiponectin in heart failure with and without cachexia: Catabolic signal linking catabolism, symptomatic status, and prognosis'. Together they form a unique fingerprint.

Cite this

Szabó, T., Scherbakov, N., Sandek, A., Kung, T., von Haehling, S., Lainscak, M., Jankowska, E. A., Rudovich, N., Anker, S. D., Frystyk, J., Flyvbjerg, A., Pfeiffer, A. F. H., & Doehner, W. (2014). Plasma adiponectin in heart failure with and without cachexia: Catabolic signal linking catabolism, symptomatic status, and prognosis. Nutrition, Metabolism and Cardiovascular Diseases, 24(1), 50-56. https://doi.org/10.1016/j.numecd.2013.04.015

Plasma adiponectin in heart failure with and without cachexia : Catabolic signal linking catabolism, symptomatic status, and prognosis. / Szabó, T.; Scherbakov, N.; Sandek, A.; Kung, T.; von Haehling, S.; Lainscak, M.; Jankowska, E. A.; Rudovich, N.; Anker, S. D.; Frystyk, J.; Flyvbjerg, A.; Pfeiffer, A. F H; Doehner, W.

In: Nutrition, Metabolism and Cardiovascular Diseases, Vol. 24, No. 1, 2014, p. 50-56.

Research output: Contribution to journal › Article › peer-review

Szabó, T, Scherbakov, N, Sandek, A, Kung, T, von Haehling, S, Lainscak, M, Jankowska, EA, Rudovich, N, Anker, SD, Frystyk, J, Flyvbjerg, A, Pfeiffer, AFH & Doehner, W 2014, 'Plasma adiponectin in heart failure with and without cachexia: Catabolic signal linking catabolism, symptomatic status, and prognosis', Nutrition, Metabolism and Cardiovascular Diseases, vol. 24, no. 1, pp. 50-56. https://doi.org/10.1016/j.numecd.2013.04.015

Szabó, T. ; Scherbakov, N. ; Sandek, A. ; Kung, T. ; von Haehling, S. ; Lainscak, M. ; Jankowska, E. A. ; Rudovich, N. ; Anker, S. D. ; Frystyk, J. ; Flyvbjerg, A. ; Pfeiffer, A. F H ; Doehner, W. / Plasma adiponectin in heart failure with and without cachexia : Catabolic signal linking catabolism, symptomatic status, and prognosis. In: Nutrition, Metabolism and Cardiovascular Diseases. 2014 ; Vol. 24, No. 1. pp. 50-56.

@article{b9fb803f9cac425398d37129ff17d0ff,

title = "Plasma adiponectin in heart failure with and without cachexia: Catabolic signal linking catabolism, symptomatic status, and prognosis",

abstract = "Background and aims: Adiponectin (ADPN) as an adipose tissue hormone contributes to regulation of energy metabolism and body composition and is associated with cardiovascular risk profile parameters. Cardiac cachexia may develop as a result of severe catabolic derangement in chronic heart failure (CHF). We aimed to determinate an abnormal ADPN regulation as a link between catabolic signalling, symptomatic deterioration and poor prognosis. Methods and results: We measured plasma ADPN in 111 CHF patients (age 65±11, 90% male, left ventricular ejection fraction (LVEF) 36±11%, peak oxygen consumption (peakVO2) 18.1±5.7l/kg*min, body mass index (BMI) 27±4 kg/m2, all mean±standard deviation) and 36 healthy controls of similar age and BMI. Body composition was assessed by dual energy X-ray absorptiometry, insulin sensitivity was evaluated by homoeostasis model assessment, exercise capacity by spiroergometry. Plasma ADPN did not differ between CHF vs. controls (13.5±11.0 vs. 10.5±5.3 mg/l, p>0.4), but increased stepwise with NYHA functional class (I/II/III: 5.7±1.4/10.7±8.3/19.2±14.0 mg/l, ANOVA p2 at anaerobic threshold (r=-0.34, p",

keywords = "Adiponectin, ADPN, AT, BMI, Cachexia, CCHF, CHF, Chronic heart failure, DEXA, HOMA, LVEF, Metabolism, NcCHF, NYHA, ProANP, RER, VE",

author = "T. Szab{\'o} and N. Scherbakov and A. Sandek and T. Kung and {von Haehling}, S. and M. Lainscak and Jankowska, {E. A.} and N. Rudovich and Anker, {S. D.} and J. Frystyk and A. Flyvbjerg and Pfeiffer, {A. F H} and W. Doehner",

year = "2014",

doi = "10.1016/j.numecd.2013.04.015",

language = "English",

volume = "24",

pages = "50--56",

journal = "Nutrition, Metabolism and Cardiovascular Diseases",

issn = "0939-4753",

publisher = "Elsevier B.V.",

number = "1",

}

TY - JOUR

T1 - Plasma adiponectin in heart failure with and without cachexia

T2 - Catabolic signal linking catabolism, symptomatic status, and prognosis

AU - Szabó, T.

AU - Scherbakov, N.

AU - Sandek, A.

AU - Kung, T.

AU - von Haehling, S.

AU - Lainscak, M.

AU - Jankowska, E. A.

AU - Rudovich, N.

AU - Anker, S. D.

AU - Frystyk, J.

AU - Flyvbjerg, A.

AU - Pfeiffer, A. F H

AU - Doehner, W.

PY - 2014

Y1 - 2014

N2 - Background and aims: Adiponectin (ADPN) as an adipose tissue hormone contributes to regulation of energy metabolism and body composition and is associated with cardiovascular risk profile parameters. Cardiac cachexia may develop as a result of severe catabolic derangement in chronic heart failure (CHF). We aimed to determinate an abnormal ADPN regulation as a link between catabolic signalling, symptomatic deterioration and poor prognosis. Methods and results: We measured plasma ADPN in 111 CHF patients (age 65±11, 90% male, left ventricular ejection fraction (LVEF) 36±11%, peak oxygen consumption (peakVO2) 18.1±5.7l/kg*min, body mass index (BMI) 27±4 kg/m2, all mean±standard deviation) and 36 healthy controls of similar age and BMI. Body composition was assessed by dual energy X-ray absorptiometry, insulin sensitivity was evaluated by homoeostasis model assessment, exercise capacity by spiroergometry. Plasma ADPN did not differ between CHF vs. controls (13.5±11.0 vs. 10.5±5.3 mg/l, p>0.4), but increased stepwise with NYHA functional class (I/II/III: 5.7±1.4/10.7±8.3/19.2±14.0 mg/l, ANOVA p2 at anaerobic threshold (r=-0.34, p

AB - Background and aims: Adiponectin (ADPN) as an adipose tissue hormone contributes to regulation of energy metabolism and body composition and is associated with cardiovascular risk profile parameters. Cardiac cachexia may develop as a result of severe catabolic derangement in chronic heart failure (CHF). We aimed to determinate an abnormal ADPN regulation as a link between catabolic signalling, symptomatic deterioration and poor prognosis. Methods and results: We measured plasma ADPN in 111 CHF patients (age 65±11, 90% male, left ventricular ejection fraction (LVEF) 36±11%, peak oxygen consumption (peakVO2) 18.1±5.7l/kg*min, body mass index (BMI) 27±4 kg/m2, all mean±standard deviation) and 36 healthy controls of similar age and BMI. Body composition was assessed by dual energy X-ray absorptiometry, insulin sensitivity was evaluated by homoeostasis model assessment, exercise capacity by spiroergometry. Plasma ADPN did not differ between CHF vs. controls (13.5±11.0 vs. 10.5±5.3 mg/l, p>0.4), but increased stepwise with NYHA functional class (I/II/III: 5.7±1.4/10.7±8.3/19.2±14.0 mg/l, ANOVA p2 at anaerobic threshold (r=-0.34, p

KW - Adiponectin

KW - ADPN

KW - AT

KW - BMI

KW - Cachexia

KW - CCHF

KW - CHF

KW - Chronic heart failure

KW - DEXA

KW - HOMA

KW - LVEF

KW - Metabolism

KW - NcCHF

KW - NYHA

KW - ProANP

KW - RER

KW - VE

UR - http://www.scopus.com/inward/record.url?scp=84894252588&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84894252588&partnerID=8YFLogxK

U2 - 10.1016/j.numecd.2013.04.015

DO - 10.1016/j.numecd.2013.04.015

M3 - Article

C2 - 23791298

AN - SCOPUS:84894252588

VL - 24

SP - 50

EP - 56

JO - Nutrition, Metabolism and Cardiovascular Diseases

JF - Nutrition, Metabolism and Cardiovascular Diseases

SN - 0939-4753

IS - 1

ER -